Managing Director, Mercury Fund
Professor of Innovation at The University of Texas at Austin
Chair, Department of Chemical Physiology, The Scripps Research Institute; Co-director, Center for Physiological Proteomics, The Scripps Research Institute
Founder, The Haul Company
Cancer occurs when a group of cells in the body lose their ability to divide in an orderly fashion. Angiogenesis, or blood vessel growth, induced by a tumor allows it to continue growing. UCSD pathologist David Cheresh studies tumor angiogenesis and tumor cell invasion and metastasis. Scientists working in his lab have developed a number of inhibitors of tumor angiogenesis that are now being tested clinically in cancer patients. Two of these agents, Vitaxin and Celingitide, show promise for late stage cancer patients and appear safe with little or no side effects. Online information and registration is available here.